6 News & Press Releases found

VisionQuest Biomedical Inc. news

“Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation Biomarkers of the Plantar Foot” Poster Presentation

VisionQuest founder and CEO Peter Soliz (PhD) presented the poster “Detecting diabetic peripheral neuropathy utilizing thermoregulation biomarkers of the plantar foot” at the American Diabetes Association’s 82nd Scientific Sessions last Sunday in New Orleans. “I was so glad to be able to meet with colleagues and make new connec

Jun. 3, 2022

Early Diabetic Peripheral Neuropathy Detection with i-RxTherm

We have submitted our third Commercialization Readiness Pilot (CRP) Program grant application to the National Institutes of Health (NIH). In it, we describe our plan to commercialize i-RxTherm, our device for early diabetic peripheral neuropathy detection and diagnosis.

Apr. 2, 2022

VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA

We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects w

Mar. 2, 2022

Turning a Great Idea into a Successful Product: ASPIRE

For VisionQuest’s vice president and principal investigator Vinayak Joshi (PhD), the journey from idea to commercial product has led him halfway around the world. Dr. Joshi recently traveled to Malawi, Kenya, Nigeria, and Ghana as part of his efforts to commercialize ASPIRE, his device for the detection and diagnosis of

Jul. 2, 2022

VQB Wins $1 Million to Commercialize System for Early Detection of DPN

VisionQuest Biomedical founder and CEO Peter Soliz (PhD) has just been awarded a $1 million Commercialization Readiness Pilot Program (CRP) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (part of the US National Institutes of Health) for his work on early detection of DPN. With the support of this grant, Dr. Soliz will develop a commercial proto

Oct. 0, 2022